COVID-19 Vaccines Resources
When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus.
This webpage is intended to help keep the supply chain field informed of important updates related to the progress and distribution of COVID-19 vaccines. Resources and information will be added and updated often as new developments occur.
AHA COVID-19 Vaccines and Therapeutics
When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus. As the virus surged in 2020, therapeutics were developed to treat those with COVID-19 in outpatient and inpatient settings. This webpage is intended to help keep the field informed of important updates related to the progress and distribution of COVID-19 vaccines, along with in-development therapeutics for patients with COVID-19.
CDC COVID-19 Vaccination Program Interim Playbook
This playbook serves as an interim playbook for state, territorial, tribal and local public health programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their jurisdictions.
COVID-19 Vaccine EUAs
Pfizer and BioNTech COVID-19 Vaccine
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. On 2/25/21, again having concluded that revising this EUA is appropriate to protect the public health or safety under section 564(g)(2) of the Act, FDA is reissuing the 12/23/20, letter in its entirety with revisions incorporated to allow flexibility on the date of submission of monthly periodic safety reports and to revise the requirements for reporting of vaccine administration errors by Pfizer Inc.
Moderna COVID-19 Vaccine
Moderna COVID‑19 Vaccine is for use for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles. It is an investigational vaccine not licensed for any indication.
Johnson & Johnson-Janssen COVID-19 Vaccine
The Johnson & Johnson-Janssen COVID‑19 Vaccine is for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) vector, encoding the SARS-CoV-2 viral spike (S) glycoprotein, stabilized in its pre-fusion form. It is an investigational vaccine not licensed for any indication.
AHRMM Webinar: COVID 19 Vaccine Supply, Distribution and Handling Overview: An Operation Warp Speed Panel Discussion
Webinar Recording and Handouts
Review the recording and materials that were made available at the December 16 webinar:
Operation Warp Speed Videos
Review the videos provided by HHS and Operation Warp Speed:
View Five Things to Know About the COVID-19 Vaccine Timeline (Video)
Access Five Things to Know About Operation Warp Speed (Video)